[
    [
        {
            "time": "",
            "original_text": "贝达药业：CM082肾癌适应症的新药注册申报准备工作正在推进中，公司会加紧安排，争取新药尽早申报上市",
            "features": {
                "keywords": [
                    "贝达药业",
                    "CM082",
                    "肾癌",
                    "新药",
                    "注册申报"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "贝达药业：CM082肾癌适应症的新药注册申报准备工作正在推进中，公司会加紧安排，争取新药尽早申报上市",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "贝达药业：传闻丁董与王博士意见分歧，严重影响公司研发项目进度不实",
            "features": {
                "keywords": [
                    "贝达药业",
                    "丁董",
                    "王博士",
                    "意见分歧",
                    "研发项目"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "贝达药业：传闻丁董与王博士意见分歧，严重影响公司研发项目进度不实",
                "Correlation": 9,
                "Sentiment": 4,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "贝达药业：凯美纳术后辅助治疗适应症已于今年6月获批上市，贝伐珠单抗类似物MIL60目前已完成相关核查，力争年内获批上市",
            "features": {
                "keywords": [
                    "贝达药业",
                    "凯美纳",
                    "术后辅助治疗",
                    "贝伐珠单抗",
                    "MIL60",
                    "获批上市"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "贝达药业：凯美纳术后辅助治疗适应症已于今年6月获批上市，贝伐珠单抗类似物MIL60目前已完成相关核查，力争年内获批上市",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 6,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        }
    ]
]